FY2025 EPS Estimates for AbbVie Reduced by Cantor Fitzgerald

AbbVie Inc. (NYSE:ABBV) – Cantor Fitzgerald lowered their FY2025 earnings per share estimates for AbbVie in a research note issued on Wednesday, April 30th. Cantor Fitzgerald analyst C. Gould now expects that the company will post earnings per share of $12.31 for the year, down from their prior estimate of $12.33. Cantor Fitzgerald has a “Overweight” rating and a $210.00 price target on the stock. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share.

A number of other research analysts have also issued reports on the stock. UBS Group boosted their target price on shares of AbbVie from $181.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Guggenheim boosted their price target on shares of AbbVie from $214.00 to $216.00 and gave the stock a “buy” rating in a research report on Tuesday. Raymond James reaffirmed an “outperform” rating and issued a $220.00 price target (up from $218.00) on shares of AbbVie in a research note on Monday, February 3rd. Citigroup raised their price objective on shares of AbbVie from $205.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Finally, Bank of America upped their target price on AbbVie from $200.00 to $223.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 4th. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $211.41.

AbbVie Price Performance

Shares of ABBV opened at $198.62 on Thursday. AbbVie has a 12 month low of $153.58 and a 12 month high of $218.66. The company has a market cap of $351.35 billion, a P/E ratio of 82.76, a PEG ratio of 1.62 and a beta of 0.56. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. The stock has a fifty day moving average price of $196.14 and a 200 day moving average price of $187.25.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a return on equity of 296.28% and a net margin of 7.59%. The firm had revenue of $13.34 billion for the quarter, compared to analysts’ expectations of $12.91 billion. During the same period last year, the business posted $2.31 earnings per share. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a dividend of $1.64 per share. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.30%. AbbVie’s dividend payout ratio is 279.15%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 5,778 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $197.90, for a total value of $1,143,466.20. Following the transaction, the executive vice president now directly owns 22,381 shares of the company’s stock, valued at $4,429,199.90. This represents a 20.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of AbbVie stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $210.08, for a total value of $12,359,426.56. Following the sale, the executive vice president now owns 53,234 shares of the company’s stock, valued at approximately $11,183,398.72. This represents a 52.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 113,471 shares of company stock valued at $23,426,451 in the last 90 days. 0.25% of the stock is currently owned by corporate insiders.

Institutional Trading of AbbVie

A number of institutional investors have recently added to or reduced their stakes in the business. Saturna Capital Corp lifted its stake in shares of AbbVie by 6.0% in the 1st quarter. Saturna Capital Corp now owns 717,186 shares of the company’s stock valued at $150,265,000 after purchasing an additional 40,521 shares during the last quarter. Burling Wealth Partners LLC raised its holdings in AbbVie by 10.5% during the first quarter. Burling Wealth Partners LLC now owns 44,078 shares of the company’s stock valued at $9,235,000 after buying an additional 4,172 shares in the last quarter. Retirement Planning Co of New England Inc. lifted its position in shares of AbbVie by 3.8% in the first quarter. Retirement Planning Co of New England Inc. now owns 20,853 shares of the company’s stock worth $4,369,000 after buying an additional 763 shares during the last quarter. Hardy Reed LLC boosted its stake in shares of AbbVie by 1.2% during the 1st quarter. Hardy Reed LLC now owns 11,648 shares of the company’s stock worth $2,440,000 after acquiring an additional 134 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI increased its holdings in shares of AbbVie by 4.9% during the 1st quarter. Commerzbank Aktiengesellschaft FI now owns 59,270 shares of the company’s stock valued at $12,419,000 after acquiring an additional 2,786 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.